Publication:
Dual immunoplatform to assess senescence biomarkers TIMP-1 and GDF-15: Advancing in the understanding of colorectal cancer

dc.contributor.authorTejerina-Miranda, Sandra
dc.contributor.authorGamella, Maria
dc.contributor.authorPedrero, María
dc.contributor.authorMontero-Calle, Ana Maria
dc.contributor.authorRejas-González, Raquel
dc.contributor.authorPingarrón, José M
dc.contributor.authorBarderas Manchado, Rodrigo
dc.contributor.authorCampuzano, Susana
dc.contributor.funderAgencia Estatal de Investigación (España)
dc.contributor.funderUnión Europea. Comisión Europea. H2020
dc.contributor.funderMinisterio de Ciencia e Innovación (España)
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderComplutense University of Madrid (España)
dc.date.accessioned2024-10-17T10:27:20Z
dc.date.available2024-10-17T10:27:20Z
dc.date.issued2024
dc.description.abstractIn this work, we report the development of electrochemical bioplatforms for both the single determination of TIMP-1 and the simultaneous determination of TIMP-1 and GDF-15, two biomarkers of cellular senescence and prognosis in colorectal cancer (CRC). The designed immunoplatforms rely on a sandwich-type configuration labeled with horseradish peroxidase (HRP) built on magnetic microsupports and involve a pair of specific an tibodies to capture and detect each target protein. Amperometric readout was performed upon trapping the magnetic bioconjugates on the surface of either single or dual disposable carbon electrodes, using the hydro quinone/hydrogen peroxide (HQ/H2O2) system. The attractive analytical performance of the TIMP-1 bio platform, achieving a LOD of 13.0 pg mL‒1 and a dynamic range between 43.4 and 2500 pg mL‒1, led us to exploit it for TIMP-1 determination in cell extracts and tissues of CRC samples. The results showed the possibility of discriminating the metastatic capabilities of cells and detecting CRC patients, after just a simple dilution and in only 60 min. The multiplexing feasibility of the developed immunoplatform allowed the implementation of a dual assay for the simultaneous determination of TIMP-1 (LOD 19.2 pg mL‒1) and GDF-15 (LOD 16.6 pg mL‒1 ). The dual platform was used for the analysis of CRC samples (plasma and cell secretomes) in just 75 min and using a very simple protocol. These characteristics make the developed immunoplatform a very attractive tool to face particularly challenging samples, such as secretomes or plasma from CRC patients, due to the required sensi tivity, thus providing a better snapshot of CRC.
dc.description.sponsorshipThe financial support of Grants PID2022#x2013;136351OB-I00 and PID2022–140307OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, EU’s Horizon 2020 funding program (UCM’s Specific Research Fund FEI-EU-22–08) and PI20CIII/00019 and PI23CIII/00027 grants from the AES-ISCIII program are gratefully acknowledged. S.T.M. acknowledges a predoc toral contract from the Spanish Ministerio de Ciencia e Innovación (PRE2020-092859).
dc.format.page144822
dc.format.volume503
dc.identifier.citationElectrochimica Acta. 2024, 503:144822.
dc.identifier.doi10.1016/j.electacta.2024.144822
dc.identifier.issn0013-4686
dc.identifier.journalElectrochimica Acta
dc.identifier.urihttps://hdl.handle.net/20.500.12105/25178
dc.language.isoeng
dc.publisherElsevier
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI20CIII/00019
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI23CIII/00027
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PRE2020-092859
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2022-140307OB-I00
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2022-2013-136351OB-I00
dc.relation.publisherversionhttps://doi.org/10.1016/j.electacta.2024.144822
dc.repisalud.centroISCIII::Unidad Funcional de Investigación de Enfermedades Crónicas (UFIEC)
dc.repisalud.institucionISCIII
dc.rights.accessRightsopen access
dc.rights.licenseAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectElectrochemical immunoplatforms
dc.subjectDual determination
dc.subjectColorectal cancer
dc.subjectCellular senescence
dc.subjectPlasma
dc.subjectTissues
dc.titleDual immunoplatform to assess senescence biomarkers TIMP-1 and GDF-15: Advancing in the understanding of colorectal cancer
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication3e80abe1-6578-487f-8201-f4c5ed3a674c
relation.isAuthorOfPublication212685cb-e351-487f-b16e-7431a0d5fcc3
relation.isAuthorOfPublicationdfb1f4f9-c8e8-4087-9db5-6477d4f154e4
relation.isAuthorOfPublication.latestForDiscovery3e80abe1-6578-487f-8201-f4c5ed3a674c
relation.isFunderOfPublication54733407-1d78-4c44-bf4c-8c8a7592aa4b
relation.isFunderOfPublicationa418cf3b-f427-4376-a75f-01dba9bb944f
relation.isFunderOfPublication289dce42-6a28-4892-b0a8-c70c46cbb185
relation.isFunderOfPublicationefa64f05-b985-4984-8f1e-5fc4ef21f502
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication3d8c0cc5-2573-4736-8464-c4f492073163
relation.isFunderOfPublication.latestForDiscovery54733407-1d78-4c44-bf4c-8c8a7592aa4b
relation.isPublisherOfPublication7d471502-7bd5-4f7a-90a4-8274382509ef
relation.isPublisherOfPublication.latestForDiscovery7d471502-7bd5-4f7a-90a4-8274382509ef

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
DualImmunoplatformAssessSenescence_2024.pdf
Size:
3.74 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Supplementary_DualImmunoplatformAssessSenescence_2024.pdf
Size:
498.5 KB
Format:
Adobe Portable Document Format